Towards a safe and effective chlamydial vaccine: Lessons from the eye

Highlights

• •

  Chlamydia trachomatis is the leading infectious cause of blindness.

• •

  Vaccine trials against ocular C. trachomatis infection were conducted in the 1960s.

• •

  Whole organism vaccines induced short-lived, strain-specific protective immunity.

• •

  Many correlates of protective immunity and pathology have been defined.

• •

  Important lessons have been learned to inform the development of a chlamydial vaccine.

Abstract

As well as being the most common bacterial sexually transmitted infection, Chlamydia trachomatis ( Ct) is the leading infectious cause of blindness. The pathogenesis of ocular chlamydial infection (trachoma) is similar to that of genital infection. In the 1960s the efficacy of Ct vaccines against ocular infection was evaluated in major field trials in Saudi Arabia, Taiwan, The Gambia, India and Ethiopia. These trials showed that it was possible to induce short term immunity to ocular infection, and to reduce the incidence of inflammatory trachoma, by parenteral immunisation with killed or live whole organism vaccines. In one study, it was also shown that the incidence of scarring sequelae was reduced in vaccinated children. Detailed studies in non-human primates conducted at this time suggested that vaccination could lead to more severe inflammatory disease on subsequent challenge. Since that time there have been many studies on the immunological correlates of protective immunity and immunopathology in ocular Ct infection in humans and non-human primates, and on host genetic polymorphisms associated with protection from adverse sequelae. These have provided important information to guide the development and evaluation of a human Ct vaccine.